Requesting and interpreting urine albumin measurements in the primary health care setting

Clinical Chemistry

Volumn 54, Issue 10, 2008, Pages 1595-1597

  McQueen, Matthew J ^a,b   Don Wauchope, Andrew C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ALBUMINOID;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; EDITORIAL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIMARY HEALTH CARE; URINE; ALBUMINURIA; DIFFERENTIAL DIAGNOSIS; NOTE; PRACTICE GUIDELINE; REFERENCE VALUE; STANDARD;

ALBUMINS; ALBUMINURIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; REFERENCE VALUES;

EID: 54049135263     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2008.113431     Document Type: Editorial

References (15)

1. US Renal Data System: US RDS 2002 Data Report: Atlas of Endstage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
2. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal 2004; 286:F442-50.
3. Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular risk in patients with chronic kidney disease. Curr Op Nephrol Hypertens 2004;13: 73-81.
4. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004;33: 189-98.
5. Hillege HL, Fidler V, Diercks GF, for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
6. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
8. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-8.
9. DeZeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-28.
10. Taal MW. Slowing the progression of adult chronic kidney disease: therapeutic advances. Drugs 2004;64:2273-89.
11. Aakre M, Thue G, Subramanian-Haavik S, Bukve T, Morris H, Müller M, et al. Postanalytical external quality assessment of urine albumin in primary health care: an international study. Clin Chem 2008;54:1630-6.
12. Howey J, Browning M, Fraser C. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. Clin Chem 1987;33:2034-8.
13. Fraser C. Biological Variation: From Principles to Practice. Washington DC: AACC Press, 2001.
14. Smellie W. What is a significant difference between sequential laboratory results? J Clin Pathol 2008;61:419-25.
15. Redon J. Measurement of microalbuminuria: what the nephrologist should know. Nephrol Dial Transplant 2006;21:573-6.